acut
respiratori
tract
infect
arti
includ
common
cold
otiti
media
pharyng
acut
bronchiol
pneumoniaar
common
diagnos
among
patient
seek
medic
care
us
account
major
antibiot
prescript
donnelli
et
al
estim
year
million
emerg
depart
ed
visit
patient
year
age
diagnosi
arti
rate
per
ed
visit
antimicrobi
indic
common
cold
bronchitisbronchiol
vast
major
pharyng
case
specif
criteria
exist
target
appropri
antibiot
use
otiti
media
sinus
streptococc
pharyng
yet
antibiot
prescrib
common
among
children
arti
bronchiti
sinus
acut
otiti
media
studi
evalu
bronchiol
manag
aap
guidelin
found
signific
reduct
rsv
test
p
decreas
corticosteroid
bronchodil
use
p
howev
trend
antibiot
use
chang
p
postaap
guidelin
period
highlight
signific
problem
overus
antibiot
arti
use
stringent
diagnost
criteria
confirm
diagnosi
arti
key
optim
antibiot
prescrib
empir
treatment
arti
remain
common
viral
symptom
often
clinic
similar
difficult
distinguish
caus
bacteria
therefor
laboratori
test
provid
accur
prompt
detect
pathogen
associ
respiratori
infect
http
receiv
august
receiv
revis
form
novemb
accept
novemb
import
proper
patient
care
manag
molecular
respiratori
panel
mrp
assay
becom
increasingli
popular
due
abil
detect
multipl
pathogen
high
sensit
specif
document
cost
save
research
demonstr
mrp
may
posit
impact
patient
outcom
decreas
empir
antibiot
exposur
length
hospit
stay
lo
improv
time
oseltamivir
treatment
influenza
patient
dearth
inform
whether
clinic
impact
condit
turnaroundtim
tat
mrp
assay
xtag
respiratori
viral
panel
rvp
biofir
respiratori
panel
rp
fdaclear
mrp
assay
detect
respiratori
pathogen
respect
object
studi
compar
impact
rvp
rp
clinic
outcom
patient
admit
hospit
hypothes
rapid
detect
respiratori
pathogen
rp
compar
rvp
would
posit
associ
chang
antibiot
treatment
initi
oseltamivir
lo
pediatr
patient
year
old
perform
retrospect
cohort
studi
pediatr
patient
admit
freestand
children
hospit
decemb
test
posit
least
one
respiratori
pathogen
either
rvp
luminex
inc
texa
rp
biofir
llc
idaho
mrp
assay
data
abstract
electron
medic
record
patient
rvp
rp
assay
occur
either
admit
inpati
ed
encount
patient
initi
seen
ed
subsequ
admit
medic
servic
consid
one
clinic
episod
patient
exclud
either
undergo
immun
suppress
therapi
admit
nicu
lo
greater
day
rvp
rp
assay
order
within
first
h
hospit
studi
review
approv
children
merci
hospit
institut
review
board
hospit
rvp
assay
introduc
decemb
replac
rp
assay
august
patient
respiratori
sampl
test
either
rvp
rp
base
test
use
date
institut
rvp
test
run
batch
mode
daili
day
week
wherea
rp
test
run
sampl
arriv
clinic
lab
primari
outcom
studi
appropri
antimicrobi
therapi
binari
treatment
indic
base
antimicrobi
use
period
mrp
assay
result
report
laboratori
inform
system
fig
includ
use
empir
system
antibiot
treatment
time
admiss
result
avail
administ
oseltamivir
influenza
posit
patient
h
follow
result
avail
preval
narrowand
broadspectrum
empir
antibiot
treatment
also
calcul
includ
durat
empir
therapi
defin
time
differ
hour
first
last
antibiot
administr
consid
penicillin
ampicillin
clindamycin
narrowspectrum
antibiot
antibiot
consid
broadspectrum
also
evalu
use
chest
radiograph
within
first
h
admiss
lo
hour
secondari
outcom
lastli
calcul
turnaroundtim
tat
ie
time
clinic
laboratori
receiv
specimen
test
complet
result
report
laboratori
inform
system
specimen
test
dichotom
studi
time
period
either
rvp
patient
rp
patient
patient
age
time
admiss
categor
either
day
infant
sepsi
workup
month
upper
age
rang
aap
guidelin
bronchiol
manag
year
older
mutual
exclus
pathogen
indic
creat
base
organ
detect
rvprp
assay
rhinoviru
enteroviru
influenza
viru
respiratori
syncyti
viru
rsv
adenoviru
human
metapneumoviru
parainfluenza
codetect
virus
bacteri
pathogen
exampl
patient
posit
rsv
categor
rsv
wherea
patient
test
posit
rsv
rhinovirusenteroviru
categor
codetect
patient
bacteri
pathogen
regardless
concurr
viral
infect
categor
bacteri
pathogen
order
depict
clinic
present
medic
decis
make
includ
locat
mrp
assay
order
picu
ed
medicalsurg
calendar
quarter
frequenc
distribut
categor
outcom
calcul
rvprp
time
period
pearson
chisquar
use
compar
proport
hospit
lo
tat
treat
continu
outcom
mannwhitney
u
test
use
compar
distribut
multivari
logist
model
use
categor
outcom
examin
relationship
rvprp
time
period
adjust
medic
servic
patient
age
pathogen
season
analysi
complet
use
sa
sa
sa
institut
cari
nc
total
patient
either
one
mrp
assay
luminex
rvp
biofir
rp
obtain
studi
time
period
initi
identifi
exclud
patient
test
neg
pathogen
sinc
focu
current
studi
describ
impact
rapid
detect
respiratori
pathogen
manag
hospit
patient
exclud
admit
either
nicu
hematologyoncolog
ward
rvprp
order
within
first
h
admiss
lo
day
seen
ed
admit
hospit
year
old
time
admiss
final
studi
group
includ
patient
total
patient
test
rvp
assay
tabl
patient
year
old
repres
largest
age
group
analysi
n
nearli
half
patient
test
posit
rhinovirusenteroviru
wherea
patient
posit
bacteri
organ
frequenc
distribut
respiratori
pathogen
two
rprvp
time
period
compar
fig
util
mrp
assay
may
increas
likelihood
optim
treatment
viral
arti
howev
sinc
studi
restrict
adult
patient
examin
clinic
impact
influenza
patient
includ
data
peak
respiratori
season
studi
need
provid
comprehens
assess
clinic
impact
pediatr
arti
patient
studi
includ
pediatr
patient
posit
respiratori
pathogen
collect
year
observ
reli
rapid
diagnost
test
arti
case
may
direct
impact
patient
manag
includ
reduc
unnecessari
antibiot
radiat
exposur
reduc
lo
despit
arti
predomin
viral
natur
empir
antibiot
treatment
arti
remain
preval
kronman
et
al
found
antibiot
frequent
prescrib
bronchiti
sinus
acut
otiti
media
patient
byington
et
al
examin
patient
receiv
direct
fluoresc
assay
respiratori
pathogen
found
patient
also
receiv
bacteri
cultur
test
posit
bacteri
infect
propos
use
mrp
assay
significantli
improv
diagnost
yield
accur
identifi
viral
etiolog
major
patient
intern
data
monitor
past
year
provid
clinician
ad
confid
antibiot
treatment
decis
find
provid
much
need
data
feder
program
insur
agenc
question
valu
mrp
assay
manag
arti
patient
feel
studi
contribut
exist
evid
rapid
molecular
diagnost
may
optim
appropri
care
manag
arti
patient
studi
found
patient
test
rp
shorter
tat
less
like
receiv
empir
antibiot
hypothes
shorter
tat
may
influenc
clinician
decis
make
delay
empir
antibiot
therapi
know
assay
result
would
avail
within
hour
studi
among
patient
test
posit
use
rapid
influenza
test
found
clinician
awar
result
significantli
less
like
prescrib
antibiot
vs
like
give
antivir
prescript
vs
rel
clinician
unawar
patient
posit
influenza
studi
patient
rp
test
result
avail
approxim
h
faster
rvp
less
like
empir
antibiot
therapi
vs
well
significantli
shorter
durat
empir
broadspectrum
vs
h
narrowspectrum
therapi
vs
h
accord
cdc
guidelin
antiinfluenza
therapi
recommend
patient
year
sign
symptom
flulik
ill
addit
multipl
observ
studi
demonstr
receipt
oseltamivir
significantli
improv
patient
outcom
patient
influenza
although
clinic
improv
like
oseltamivir
initi
shortli
symptom
onset
prospect
studi
icu
influenza
patient
compar
earli
treatment
vs
late
treatment
oseltamivir
administr
found
earli
treatment
shorter
icu
lo
vs
day
shorter
hospit
lo
vs
day
decreas
likelihood
mortal
vs
studi
nearli
rp
influenza
patient
receiv
oseltamivir
within
h
result
avail
compar
rvp
influenza
patient
util
test
shorter
tat
may
ensur
optim
treatment
influenza
infect
given
determin
cost
effect
import
hospit
decid
adopt
rapid
diagnost
test
increas
number
studi
conclud
rapid
diagnost
test
arti
virus
provid
cost
save
studi
rp
patient
decreas
empir
antibiot
use
decreas
likelihood
chest
xray
shorter
lo
could
translat
decreas
hospit
cost
cost
effect
research
need
also
consid
cost
rapid
test
patient
test
posit
limit
studi
exclud
patient
seen
either
nicu
hematologyoncolog
ward
well
patient
lo
day
howev
purpos
exclud
patient
attempt
sampl
otherwis
healthi
children
second
singlecent
studi
freestand
pediatr
hospit
therefor
result
may
gener
center
provid
care
arti
third
examin
concurr
bacteri
infect
could
partli
explain
empir
antibiot
treatment
sinc
preval
concurr
bacteri
infect
unlik
influenc
assay
type
ie
rvprp
would
argu
potenti
bias
result
minim
observ
less
human
metapneumoviru
influenza
case
rp
phase
may
influenc
treatment
strategi
especi
oseltamivir
use
patient
test
never
admit
exclud
thu
inpati
sampl
may
repres
patient
sever
arti
symptom
lastli
exclud
patient
test
neg
thu
studi
provid
complet
represent
arti
patient
rather
address
import
rapid
respiratori
pathogen
detect
manag
hospit
patient
intend
conduct
futur
research
mrp
assay
includ
neg
posit
patient
studi
demonstr
adopt
mrp
assay
shorter
tat
signific
improv
pediatr
inpati
viral
arti
includ
decreas
exposur
empir
antibiot
decreas
exposur
chest
xray
increas
optim
time
oseltamivir
administr
shorter
lo
provid
respiratori
pathogen
result
time
manner
rapid
diagnost
abil
help
guid
clinician
judici
antibiot
use
arti
patient
none
none
